Loading...
Loading...
Dr. Reddy's Laboratories
RDY today issued a
statement acknowledging that it has received a warning letter issued by
the US FDA dated November 05, 2015 relating to its API manufacturing
facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as
well as Oncology Formulation manufacturing facility at Duvvada,
Visakhapatnam, Andhra Pradesh. This action follows the earlier
inspections of these sites by the agency in November 2014, January 2015
and February 2015, respectively.
Dr. Reddy's CEO, G V Prasad commented, "We take quality and compliance
matters seriously and stand by our commitment to fully comply with the
cGMP quality standards across all of our facilities. We will respond
with a comprehensive plan to address these
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in